CALCIMEDICA INC (CALC) Stock Price, Forecast & Analysis
USA - NASDAQ:CALC - US38942Q2021 - Common Stock
CALC Key Statistics, Chart & Performance
The current stock price of CALC is 3.16 USD. In the past month the price increased by 2.93%. In the past year, price decreased by -8.41%.
CALC Latest News, Press Relases and Analysis
CALC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.44 | 987.43B | ||
| JNJ | JOHNSON & JOHNSON | 19.56 | 489.06B | ||
| MRK | MERCK & CO. INC. | 10.78 | 237.21B | ||
| PFE | PFIZER INC | 7.62 | 138.73B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7 | 93.51B | ||
| ZTS | ZOETIS INC | 18.28 | 51.36B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.34 | 22.39B | ||
| VTRS | VIATRIS INC | 4.37 | 11.88B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.13 | 10.55B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.28 | 7.91B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.15B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 3.81B |
Related stock screener links
About CALC
Company Profile
CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2020-09-25. The firm focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
Company Info
CALCIMEDICA INC
505 Coast Boulevard South, Suite 307
La Jolla CALIFORNIA US
Employees: 14
Phone: 18589525500
CALCIMEDICA INC / CALC FAQ
What does CALCIMEDICA INC do?
CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2020-09-25. The firm focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
What is the current price of CALC stock?
The current stock price of CALC is 3.16 USD. The price increased by 0.13% in the last trading session.
Does CALC stock pay dividends?
CALC does not pay a dividend.
How is the ChartMill rating for CALCIMEDICA INC?
CALC has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is CALCIMEDICA INC (CALC) stock traded?
CALC stock is listed on the Nasdaq exchange.
Would investing in CALCIMEDICA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CALC.
Can you provide the short interest for CALC stock?
The outstanding short interest for CALCIMEDICA INC (CALC) is 0.48% of its float.
CALC Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CALC. When comparing the yearly performance of all stocks, CALC turns out to be only a medium performer in the overall market: it outperformed 64.55% of all stocks.
CALC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CALC. CALC may be in some trouble as it scores bad on both profitability and health.
CALC Financial Highlights
Over the last trailing twelve months CALC reported a non-GAAP Earnings per Share(EPS) of -1.64. The EPS decreased by -17.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.45% | ||
| ROE | -173.33% | ||
| Debt/Equity | 0.79 |
CALC Forecast & Estimates
10 analysts have analysed CALC and the average price target is 16.32 USD. This implies a price increase of 416.46% is expected in the next year compared to the current price of 3.16.